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Abstract
Background: Candida parapsilosis was the most common species causing candidemia in the 2010 China Hospital
Invasive Fungal Surveillance Net (CHIF-NET) database. Compared to Candida albicans, the description of azole
resistance and mechanisms in C. parapsilosis is very limited. We report a patient with C. parapsilosis candidemia over
several months, due to a probable intravascular source, who developed fluconazole resistance after prolonged
treatment.
Case presentation: An 82 year-old male had a hospital admission of approximately 1.5 years duration. He was
initially admitted with acute pancreatitis. Prior to succumbing to the illness, he developed candidemia and treated
with three antifungal drugs for nearly 5 months, at suboptimal doses and without source control. Following
treatment, 6 blood cultures were still positive for C. parapsilosis. The last 2 strains were resistant to fluconazole
(MICs 32 μg/mL) and intermediate to voriconazole (MICs 0.5 μg/mL). Microsatellite multilocus analysis indicated that
the 6 isolates from the patient belonged to a single genotype. The first 4 isolates were susceptible to fluconazole
(MICs 2 μg/mL) and voriconazole (MICs 0.015-0.03 μg/mL), which were slightly higher than susceptible control
strains from other patients. Overexpression of MDR1 genes were detected in the two resistant isolates, and this was
associated with a homozygous mutation in MRR1 genes (T2957C /T2957C), with the amino acid exchange L986P.
Conclusions: This case corroborates that the resistant C. parapsilosis isolates can emerge in the setting of
complicated infections and the extensive use of antifungal agents, emphasizing the need for standardizing and
improving the antifungal treatment as well as source control in the treatment of infection diseases.
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Background
Candida parapsilosis is a significant clinical pathogen
that can grow in total parenteral nutrition, form biofilms
on catheters and other implanted devices, persist in the
hospital environment and be nosocomially transmitted
by hand carriage [1–4]. In China, C. parapsilosis was the
most common species causing candidemia in the 2010
China Hospital Invasive Fungal Surveillance Net (CHIF-
NET) study [5].
Azoles are the most commonly used drugs for the
treatment of Candida infections. Besides species that
show intrinsic resistance, such as Candida krusei, the ac-
quisition of azole resistance, particularly after prolonged
exposure and prophylactic overuse, is well described in
Candida albicans, Candida tropicalis, Candida glabrata
[6–9]. However, the descriptions of azole resistance in C.
parapsilosis are very limited [10, 11].
Constitutive overexpression of 2 types of multidrug
efflux pumps, encoded by CDR1 or MDR1 genes is a
major cause of resistance to azoles [12–14]. Morschhäuser
et al. found that gain of function mutations in MRR1
genes cause constitutive MDR1 overexpression in
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fluconazole-resistant C. albicans and C. dubliniensis
[15–17]. Similarly, the mutations in TAC1, a transcrip-
tion factor regulating CDR genes, are responsible for
the constitutive high-level expression of CDR genes
[18, 19]. Another common mechanism is the ERG11
gene overexpression or acquisition of mutations, result-
ing in target enzyme up-regulation or reduced affinity
to bind azoles [12–14]. The mutations in UPC2 are a
frequent cause of ERG upregulation [20].
We encountered a case of induced fluconazole resist-
ance in C. parapsilosis from a patient with persistent
candidemia due to a probable intravascular source in the
Peking Union Medical College Hospital (PUMCH). Here
we describe the case and explore the possible resistance
mechanism.
Case presentation
An 82 year-old male was admitted to the PUMCH in
December, 2008 with severe, acute pancreatitis. He was
managed with mechanical ventilation and received par-
enteral nutrition, diuretics and anti-microbial therapy.
His renal function deteriorated in the 11th week follow-
ing hospitalization, he began haemodialysis, 3 times per
week, through a left internal jugular venous catheter. In
the 49th week, he developed a fever of 39 °C, and blood
culture were collected. He was treated with empirical
meropenem and his fever resolved after 3 days. His
blood culture were positive for C. parapsilosis after
7 days, however, due to his clinical improvement he was
not given any antifungal therapy (Fig. 1). In the 52nd
week, the left internal jugular venous catheter was re-
moved, and an arteriovenous fistula was created in the
forearm using a polytetrafluoroethylene (PTFE) graft to
allow hemodialysis. In the 66th week, he became febrile
and a sputum smear showed a large amount of yeast,
with culture positive for C. glabrata. CT scan of the
chest showed nodules in the right upper lobe and bilat-
eral pleural effusion. He was treated for a pulmonary
fungal infection, with fluconazole (100 mg/day, renal
dose adjusted) (Fig. 1). While still on the antifungal
therapy, C. parapsilosis susceptible to fluconazole was
isolated from blood culture in the 71st week following
admission. In the subsequent 9 weeks the patient had
intermittent fevers. There were 4 other blood cultures
positive for C. parapsilosis, consistent with an intravas-
cular source of infection (Fig. 1). The final two isolates
(PU123 and PU127) were resistant to fluconazole and
had intermediate susceptibility to voriconazole.
Antifungal treatment received by the patient and iso-
lated strains are summarized in Fig. 1. Due to flucona-
zole treatment failure, it was changed to intraconazole
(100 mg/day) in the 74th week. This was ceased in the
76th week and fluconazole was recommenced at a higher
dose (200 mg/day). As a possible source of infection, the
synthetic arteriovenous fistula was removed in the 78th
week. However, the candidemia persisted and in the 80th
week caspofungin (50 mg/day) was commenced.
In the 81st week, the patient became comatosed
(Glasogow Coma Scale 5) with hypertonia, a positive
Babinski sign, and neck rigidity, indicative of central
nervous system infection or metabolic encephalopathy.
No further investigations were performed, as treatment
was withdrawn following discussion with the patient’s
family. The patient died in the 82nd week of admission.
Comparison with control isolates
The use of the isolates in the present study was ap-
proved by the Human Research Ethics Committee of
Peking Union Medical College Hospital (No. S-263).
We have obtained the writing consent from the control
patients to publish the case report.
There were 6 blood culture isolates from the patient
described in the case study (patient 1). In addition, 6 iso-
lates of C. parapsilosis obtained from the other patients
(patients 2–7) in the PUMCH during the hospitalization
of patient 1 were studied for control purpose. Identifica-
tion of C. parapsilosis was confirmed by DNA sequen-
cing of the fungal internal transcribed spacer (ITS)
region and the D1/D2 domain of the 28S rRNA gene,
using a published protocol [5].
Fig. 1 The antifungal treatment course and isolated C. parapsilosis strains information of the patient. aSputum smear showed a large amount of
yeast and antifungal treatment was commenced. bThe patient died of systemic invasive fungal infection and chronic renal failure
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Sensititre YeastOne YO10 broth microdilution suscep-
tibility panels (TREK Diagnostic Systems, Westlake,
Ohio) were used to test the susceptibility of C. parapsi-
losis to antifungal agents, according to a published
protocol [21]. For C. parapsilosis, the interpretation of
fluconazole, voriconazole and three echinocandins sus-
ceptibilities was done in accordance with CLSI M27-S4
[22]. Table 1 summarizes the in vitro susceptibility re-
sults of the 12 C. parapsilosis isolates. There was no sig-
nificant difference in the drugs tested except for
fluconazole and voriconazole. The isolates from patients
2–7 were susceptible to fluconazole (MICs 0.25-0.5 μg/
mL) and voriconazole (MICs ≤0.008 μg/mL) (Table 1).
For patient 1, isolates PU017, PU110, PU112 and PU116
were susceptible to fluconazole (MICs 2 μg/mL) and
voriconazole (MICs 0.015-0.03 μg/mL), but with higher
MICs than the other susceptible strains. Isolates PU123
and PU127 were resistant to fluconazole (MICs 32 μg/
mL) and had intermediate susceptibility to voriconazole
(MICs 0.5 μg/mL) (Table 1).
All the strains were genotyped using the highly poly-
morphic microsatellite markers, B5, CP1, CP4 and CP6
[23]. Amplification reactions were performed as previ-
ously reported [23]. The microsatellite multilocus geno-
types allowed the differentiation of the 12 strains from 7
patients into 6 different genotypes. The 6 isolates from
patient 1 involved a single genotype (genotype A). The
strains isolated from control patients 2–4 and 6, 7 were
assigned to genotypes B to G based on the observed differ-
ences. Isolate PU106 from the control patient 5 showed
the same pattern on microsatellite sequence analysis as
the isolates from patient 1 and designated genotype A
(Table 1).
Primers used for PCR amplification of MRR1, TAC1,
UPC2, and ERG11 genes were listed in Table 2 (11).
After alignment of the MRR1 sequences from the 12
Table 1 C. parapsilosis strains information, antifungal susceptibilities, microsatellite typing results and the MRR1 gene mutations
Strain no.a Patient Wardb Susceptibility results by Sensititre YeastOnec (μg/mL) Multilocus genotyped Genotypee MRR1
FLC VRC ITC POS ANF MCF CAS 5FC AMB B5 CP1 CP4 CP6

































































































































aAll strains were isolated from blood cultures
bEGW Emergency general ward
cFLC Fluconazole, VRC Voriconazole, ITC Itraconazole, POS Posaconazole, ANF Anidulafungin, MCF, Micafungin, CAS Caspofungin, 5FC 5-Flucytosine, AMB Amphotericin B.
Clinical breakpoints for susceptible, intermediate, and resistant for C. parapsilosis, respectively, were those of the CLSI M27-S4 for fluconazole (≤2/4/ ≥8 μg/mL); and for
voriconazole (≤0.125/0.25/≥1 μg/mL); and for anidulafungin, caspofungin, and micafungin (≤2/4/≥8 μg/mL)
dThe numbers indicate the fragment size in base pairs of the different alleles obtained with the listed marker
eThe genotype was designated according to the different microsatellite typing results
fThe PU106 isolate yielded identical genotype with the isolates from patient 1
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isolates, a single nucleotide mutation (T2957C/WT) was
detected in PU017, PU110, PU112 and PU116 compared
with the MRR1 sequence of C. parapsilosis ATCC 22019
and the control strain with the same pattern on micro-
satellite typing, PU106 genotype A (Table 1). This muta-
tion results in the replacement of a leucine amino acid
residue with a proline (L986P). In the PU123 and PU127
isolates from patient 1, mutations were found in both
alleles (T2957C/T2957C). After alignment of TAC1,
UPC2, and ERG11 gene sequences from the 12 isolates,
no mutation was found.
Overnight C. parapsilosis cultures were diluted to an
optical density at 600 nm (OD600) of 0.2 in YPD medium
and then incubated at 35 °C with shaking at 150 rpm for
additional 6 h to mid-log phase. Total RNA was ex-
tracted from isolates grown in YPD medium using the
Yeast RNAiso Reagent Kit (TaKaRa, Tokyo, Japan) and
reverse transcribed to cDNA using the PrimeScript RT
Reagent Kit (TaKaRa, Tokyo, Japan) according to the in-
structions of the manufacturer. The quantitative real-
time RT-PCRs were performed in triplicate using the
SsoFast EvaGreen supermix (Bio-Rad, Hercules, CA,
USA) on a BioRad CFX96 system. ATCC 22019 were
used as the control isolate. The primers used in this
study were listed in Table 3 [11, 24, 25]. The ACT1 gene
was used as the endogenous control. The change in fold
expression was obtained by calculating 2-ΔΔCT, and a
change of 2.5 times was considered to be overexpressed
[26]. The 2 resistant isolates from patient 1 had higher
expression levels of MRR1 than the four susceptible
isolates from patient 1 (PU123 10.5-fold and PU127
9.5-fold; Fig. 2). The 4 susceptible isolates showed
higher expression levels (>2.5 fold) than the controls.
The MDR1 expression was further increased in the re-
sistant isolates (PU123 51.0-fold and PU127 39.4-fold).
In contrast, the CDR1, UPC2, ERG11 genes expression
levels in the 2 azole-resistant isolates were not significantly
different from the 4 susceptible isolates from patient 1
and the control isolates.
In order to confirm that only MRR1 and MDR1 genes
were overexpressed, we subcultured isolates in the
presence of sub-inhibitory concentrations of fluconazole,
and repeated the gene expression studies. Two suscep-
tible isolates (PU017, PU116), the 2 resistant isolates
(PU123 and PU127) from patient 1, 3 control isolates
(PU090, PU106 and PU131) were subcultured. All the
tested isolates and the control strain ATCC 22019 were
firstly incubated at 37 °C for 4 h in RPMI 1640 (Sigma,
USA). Fluconazole was then added at a concentration of
1/2 MIC and the isolates were incubated for an add-
itional 4 h. RNA extraction and the quantitative real-
time RT-PCRs were performed as the previous experi-
ment in the present study.
The 2 resistant isolates showed higher expression
levels of MRR1 than the other isolates (PU123 3.90-fold
and PU127 3.99-fold; Table 4). The MDR1 expression
was also obviously increased in the resistant isolates
(PU123 9.70-fold and PU127 9.01-fold). Similar to the
previous experiment, the CDR1, UPC2, ERG11 genes ex-
pression levels in the 2 azole-resistant isolates were not
higher than other susceptible isolates.
Discussion
Compared to other Candida species, C. parapsilosis
tends to be associated with higher MICs to echinocan-
dins [27]. Therefore, the development of azole resistant
C. parapsilosis has significant clinical implications, as
multiazole- and multiechinocandin-resistant isolates
would limit available treatment options [10]. In addition,
there could be nosocomial transmission of resistant C.
parapsilosis between vulnerable patient groups [1–4].
Microsatellite genotyping was consistent with flucona-
zole resistant developing in previously susceptible strains
of C. parapsilosis. The 2 resistant patient-isolates
(PU123 and PU127) overexpressed MRR1 and MDR1.
The MRR1 overexpression was highly associated with
mutation (T2957C), leading to the amino acid exchange,
Table 2 Sequences of primers used in genes sequencing









Table 3 Sequences of primers used in quantitative real-time
RT-PCR
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Fig. 2 Quantitative real-time RT-PCR analysis of MDR1 (a), MRR1 (b), CDR1 (c), ERG11 (d) and UPC2 (e) genes expression levels in the 6 isolates from
patient 1 and 6 susceptible isolates from other patients. Each sample was processed in triplicate. Error bars show the standard deviations
Table 4 Gene expression in the eight C. parapsilosis isolates cultured in the presence of fluconazole with concentrations of 1/2 MIC











ATCC22019a 1.00 0.04 1.00 0.03 1.00 0.02 1.00 0.04 1.00 0.03
PU017 2.38 0.09 1.74 0.04 0.81 0.03 0.87 0.02 1.04 0.03
PU116 2.33 0.13 1.55 0.10 1.03 0.06 1.08 0.06 1.16 0.06
PU123 9.70 0.63 3.90 0.20 0.21 0.01 0.26 0.15 0.31 0.02
PU127 9.01 0.28 3.99 0.14 0.28 0.01 0.35 0.01 0.37 0.02
PU090 2.16 0.10 0.74 0.03 0.77 0.03 0.55 0.03 0.53 0.02
PU106 1.45 0.07 1.55 0.05 1.55 0.04 1.13 0.05 1.86 0.07
PU131 1.17 0.04 1.31 0.05 0.95 0.02 0.52 0.01 0.52 0.02
aATCC22019 isolates was used as control isolate, and was also cultured in the presence of 1/2 MIC of fluconazole
bAll the samples for each gene were tested in triplicate. The left column shows the mean value of expression, and the right column shows the Standard Error of
Mean (SEM)
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L986P. This indicates that the C. parapsilosis resistance
to fluconazole was conferred by the increased expression
of the MRR1 transcription factor, which resulted in a
concomitant overexpression of MDR1.
The previous studies have demonstrated that a gain-
of-function mutation in one MRR1 allele results only in
slightly decreased susceptibilities to the azoles and the
loss of heterozygosity further increases drug resistance
[15, 16]. A similar observation was made in the present
study, where the patient isolates that were heterozygous
MRR1 (T2957C/WT) mutants showed slightly higher
MICs than wild type strains (WT/WT). The last 2 iso-
lates became homozygous (T2957C/T2957C) mutants
and showed much higher MICs and overexpression of
MDR1. While this mutation was the probable cause of
the phenotypic resistance in this case, a mutagenesis
study that demonstrated the development of resistance
and increased gene expression in a previously sensitive
organism would provide additional evidence.
After repeating the experiment in which the strains
were cultured in media containing fluconazole with con-
centrations of 1/2 MIC for each isolate, we confirmed
that only MDR1 and MRR1 were overexpressed in 2 re-
sistant isolates. However, MDR1 expression did not in-
crease as much as in the initial experiment. This may be
related to different medium as well as all the isolates, in-
cluding the control isolate ATCC22019, being exposed
to fluconazole. The ERG11 genes in resistant isolates
were not overexpressed, even following to fluconazole.
Similarly, Grossman et al. has sequenced the ERG11 and
MRR1 genes in 30 fluconazole resistant C. parapsilosis
isolates and 37 susceptible dose-dependent isolates, and
found no isolate with both the MRR1 and ERG11 gene
mutation [28]. In most cases, phenotypes of resistance
developed due to a combination of mechanisms, so the
whole genome sequencing will be included in subse-
quent investigation.
This case corroborates that the resistant C. parapsilo-
sis isolates can emerge in the setting of complicated in-
fections and the extensive use of antifungal agents.
Patient 1 received fluconazole treatment for more than
3 months. However, treatment was not instituted for the
first candidemia and when fluconazole treatment was
commenced it was initially at a lower dose because of
chronic renal failure, and on the basis of sputum micros-
copy. In the previous studies, suboptimal fluconazole
dosing has leaded to the development of resistance in
Candida species [6, 29]. In addition, itraconazole was
used for 2 weeks, when it is not recommended for inva-
sive candidiasis [30]. This highlights the need for
standardization of antifungal treatment, in terms of drug
selection, dose and duration [31].
In this case, probable sources of the persistent candi-
demia were the intravenous hemodialysis catheter and
the synthetic vascular graft. Vascular catheters have been
regarded as the source in more than 50 % of cases of C.
parapsilosis candidemia and prompt removal of the
catheter is recommended [32].
Conclusions
This report described a case where fluconazole resistant
C. parapsilosis emerged during prolonged antifungal
treatment, with associated MDR1 overexpression, which
was related to a MRR1 mutation (T2957C). Resistant C.
parapsilosis has the potential to complicate the manage-
ment of candidemia in vulnerable patient groups. This
case illustrates the need for effective antifungal treat-
ment, source control in the treatment of infection
diseases.
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